LYSOGENE Revenue and Competitors
Estimated Revenue & Valuation
- LYSOGENE's estimated annual revenue is currently $1.9M per year.
- LYSOGENE's estimated revenue per employee is $155,000
Employee Data
- LYSOGENE has 12 Employees.
- LYSOGENE grew their employee count by -56% last year.
LYSOGENE's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder, CEO | Reveal Email/Phone |
2 | VP, Head Analytical sciences | Reveal Email/Phone |
3 | Chief Scientific Officer | Reveal Email/Phone |
4 | Chief Medical Officer | Reveal Email/Phone |
5 | Chief Patient Access Officer | Reveal Email/Phone |
6 | Chief Regulatory Officer & QA | Reveal Email/Phone |
7 | Director technical operations | Reveal Email/Phone |
8 | Senior scientific Manager/non-clinical project manager | Reveal Email/Phone |
9 | Associate Project Manager | Reveal Email/Phone |
10 | des Aulnois | Reveal Email/Phone |
LYSOGENE Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is LYSOGENE?
Lysogene is a biopharmaceutical gene therapy company with lead programs in neurodegenerative lysosomal storage disorders that affect children. Founded in 2009 by Karen Aiach, whose own child was affected by a neurodegenerative disease, Lysogene is rooted in a deep and compassionate understanding of the impact these diseases have on patients and families. Karen's personal experience fuels her determination to deliver real solutions that will improve patient outcomes and enhance quality of life for both patients and caregivers. Over the past 10 years, Lysogene has acquired deep experience in developing gene therapies—from early discovery through the clinical, registration and review phases. Our strong science and execution track record has been validated by our partnership with Sarepta Therapeutics and the support of top-tier investors, with nearly $100m raised since inception. More information about LYSOGENE at: www.lysogene.com
keywords:N/A
N/A
Total Funding
12
Number of Employees
$1.9M
Revenue (est)
-56%
Employee Growth %
N/A
Valuation
N/A
Accelerator
LYSOGENE News
Lysogene (FR0013233475 LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases,...
Lysogene Enters into an Exclusive Worldwide License Agreement with Yeda, the Commercial Arm of the Weizmann Institute of Science, for a Novel...
Lysogene and the Weizmann Institute signed deal to develop AAV-based gene therapy for treating neuronopathic Gaucher disease and PD in 2020.
Other Companies in NEUILLY sur SEINE
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1M | 12 | 9% | N/A |
#2 | $1.6M | 18 | N/A | N/A |
#3 | $1.9M | 19 | -14% | N/A |
#4 | $3.4M | 42 | 5% | N/A |
#5 | $6.9M | 53 | 39% | N/A |